{"DataElement":{"publicId":"6564402","version":"1","preferredName":"Patient New Or Progressive Metastatic Brain Disease Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to new or progressive metastatic brain disease as outlined in the protocol.","longName":"PT_NW_PRG_MEST_BRN_DZ_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6564397","version":"1","preferredName":"Patient New Clinical Trial Eligibility Criteria Or Progressive Metastatic Brain Disease or Disorder","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Having no previous example or precedent or parallel; of a kind not seen before._._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Advancing in extent or severity._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria","longName":"2233604v1.0:6564409v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6564409","version":"1","preferredName":"New Or Progressive Metastatic Brain Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"Having no previous example or precedent or parallel; of a kind not seen before.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Advancing in extent or severity.:A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.:An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6564409v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Progressive","conceptCode":"C25254","definition":"Advancing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Brain","conceptCode":"C12439","definition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2F7BAB-D9AE-671E-E053-F662850ADFDC","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"ONEDATA","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2ED1C4-AB16-4FB5-E053-F662850A835D","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2019-03-13","changeDescription":"11/21/18 curated for 10204. LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If patient has new or progres","type":"Preferred Question Text","description":"If patient has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required for at least 4 weeks (or scheduled assessment after the first cycle of treatment), and a risk-benefit analysis (discussion) by the patient and the investigator favors participation in the clinical trial?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If registered to the randomized Phase 2 portion, does patient have brain metastasis or a history of brain metastasis?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient (Phase 1 portion) has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first 2 cycles of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has new or progressive CNS metastases (active metastases) or leptomeningeal disease, has the investigator determined that immediate CNS-directed treatment is not required and is unlikely to be required for at least 6 weeks after initiation, and a risk-benefit analysis (discussion) by the patient and investigator favors participation in the trial?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient have new or progressive brain metastases (active brain metastases) or leptomeningeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient have new or progressive brain metastases or leptomeningeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has untreated or progressive brain metastases (active brain metastases), has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, is patient asymptomatic and the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text_1","type":"Alternate Question Text","description":"Does the treating physician determine that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_2","type":"Alternate Question Text","description":"Does the patient have new or progressive brain metastases (active brain metastases) or leptomeningeal disease?","url":null,"context":"NRG"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient has new or progressive brain metastases (active brain metastases) or leptomeningeal disease, has the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2F2BD5-FB0C-1875-E053-F662850A96B6","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeDescription":"2020-7-27 AQT added for protocol 10389. AK 11/21/18 for EC10204 LS","administrativeNotes":"2022.12.20 AQT added for ticket request CADSR0001812.ak","unresolvedIssues":null,"deletedIndicator":"No"}}